Arch Introduces New Supplemental Health Insurance Products to Help Bridge Coverage Gaps
These products are designed to help individuals manage out-of-pocket expenses not typically covered by major medical plans, including deductibles, co-insurance and out-of-network charges through a variety of benefits including Accident Medical Expense, Hospital Indemnity, Critical Illness and Accidental Death. Arch's products provide an added layer of financial cushion when unexpected health events occur to individuals including employees, independent contractors, gig workers and association members.
The products are available with no medical underwriting and are fully portable, allowing policyholders to keep their coverage through job or life changes. Arch's digital technology enables partners to generate quotes and complete enrollments in minutes. Arch's fully licensed call center provides sales and customer service support for both partners and clients.
'By offering access through our APEX™ digital platform or seamless API integration, we're making it easier than ever for our distribution partners to deliver these products efficiently and effectively to their clients,' said Jim Villa, Senior Vice President, Arch Accident & Health.
For more information or to schedule a call to discuss how our individual supplemental health products can add value to your company, please visit our website or contact us at accidentandhealth@archinsurance.com.
About Arch Accident & Health
Arch Accident & Health is a leading provider of innovative insurance solutions, committed to redefining industry standards through technological advancements and unparalleled client support. With a focus on excellence and a dedication to delivering value-driven products, Arch Accident & Health continues to lead the way in the insurance sector.
About Arch Insurance North America
Arch Insurance North America, part of Arch Capital Group Ltd., includes Arch's insurance operations in the United States and Canada. Business in the U.S. is written by Arch Insurance Company, Arch Specialty Insurance Company, Arch Property & Casualty Insurance Company and Arch Indemnity Insurance Company. Business in Canada is written by Arch Insurance Canada Ltd.
About Arch Capital Group Ltd.
Arch Capital Group Ltd., a publicly listed Bermuda exempted company with approximately $22.1 billion in capital at March 31, 2024, provides insurance, reinsurance and mortgage insurance on a worldwide basis through its wholly owned subsidiaries.
Cautionary Note Regarding Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward−looking statements. This release or any other written or oral statements made by or on behalf of Arch Capital Group Ltd. and its subsidiaries may include forward−looking statements, which reflect the Company's current views with respect to future events and financial performance. All statements other than statements of historical fact included in or incorporated by reference in this release are forward−looking statements.
Forward−looking statements can generally be identified by the use of forward−looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe" or "continue" or their negative or variations or similar terminology. Forward−looking statements involve the Company's current assessment of risks and uncertainties. Actual events and results may differ materially from those expressed or implied in these statements. A non-exclusive list of the important factors that could cause actual results to differ materially from those in such forward-looking statements includes the following: adverse general economic and market conditions; increased competition; pricing and policy term trends; fluctuations in the actions of rating agencies and the Company's ability to maintain and improve its ratings; investment performance; the loss of key personnel; the adequacy of the Company's loss reserves, severity and/or frequency of losses, greater than expected loss ratios and adverse development on claim and/or claim expense liabilities; greater frequency or severity of unpredictable natural and man-made catastrophic events, including the effect of contagious diseases on our business; the impact of acts of terrorism and acts of war; changes in regulations and/or tax laws in the United States or elsewhere; ability to successfully integrate, establish and maintain operating procedures as well as integrate the businesses the Company has acquired or may acquire into the existing operations; changes in accounting principles or policies; material differences between actual and expected assessments for guaranty funds and mandatory pooling arrangements; availability and cost to the Company of reinsurance to manage our gross and net exposures; the failure of others to meet their obligations to the Company; an incident, disruption in operations or other cyber event caused by cyber attacks, the use of artificial intelligence technologies or other technology on the Company's systems or those of the Company's business partners and service providers, which could negatively impact the Company's business and/or expose the Company to litigation; and other factors identified in our filings with the U.S. Securities and Exchange Commission (SEC).
The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with other cautionary statements that are included herein or elsewhere. All subsequent written and oral forward−looking statements attributable to us or persons acting on the Company's behalf are expressly qualified in their entirety by these cautionary statements. The Company's forward-looking statements speak only as of the date of this press release or as of the date they are made, and the Company undertakes no obligation to publicly update or revise any forward−looking statement, whether as a result of new information, future events or otherwise.
Source — Arch Insurance North America
Tag — arch-insurance
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Israeli forces kill 63 Palestinian in Gaza within hours of ‘humanitarian pause'
The Israeli military killed at least 63 people across Gaza just hours after declaring daily 'pauses' in operations to facilitate the passage of humanitarian aid, health officials said. The military said on Sunday it would suspend operations daily from 10am until 8pm in parts of central and northern Gaza, including al-Mawasi, Deir el-Balah and Gaza City, and promised to open aid corridors from 6am to 11pm to let in food and medical supplies. However, within hours of the so-called 'humanitarian pause' taking effect, Israeli forces resumed air raids. One reported strike targeted a bakery in an area designated as a 'safe zone', according to Al Jazeera. The humanitarian crisis continued to worsen. Health officials reported six more deaths, including of two children, from starvation in the past 24 hours, taking the total to 133. Among the latest to succumb was five-month-old Zainab Abu Haleeb, who died of malnutrition at the Nasser Hospital. 'Three months inside the hospital and this is what I get in return, that she is dead,' her mother Israa Abu Haleeb told Al Jazeera. The World Food Programme said one in three people in Gaza had gone days without food and about half a million were experiencing famine-like conditions. More than 20 per cent of pregnant and breastfeeding women were malnourished, according to the World Health Organization. Israel maintains that it is working to improve aid access and denies that famine exists in Gaza. But aid organisations say the situation is catastrophic, with a quarter of the population at risk of acute malnutrition. UN officials say the crisis won't ease unless Israel speeds up the movement of aid convoys through its checkpoints. A top UN official said last week Palestinians were beginning to resemble 'walking corpses'. Philippe Lazzarini, head of the UN agency for Palestinian refugees, Unrwa, said humanitarian workers were encountering children who were 'emaciated, weak and at high risk of dying' without immediate intervention. 'Families are no longer coping. They're breaking down, unable to survive,' Mr Lazzarini said. 'Their existence is threatened.' Israel has severely limited the flow of food and humanitarian aid into Gaza, allowing only a small number of trucks to enter each day after enforcing an 11-week total blockade earlier this year. UN officials warn the current level of aid is merely a drop in the ocean compared to the scale of need. The Israeli military intercepted an aid ship bound for Gaza that aimed to breach the blockade on the Palestinian territory, detaining 21 international activists and journalists and confiscating all cargo, including baby formula, food, and medicine, according to the Freedom Flotilla Coalition on Sunday. The group said Israeli forces 'violently intercepted' their vessel, Handala, in international waters around 40 nautical miles off the coast of Gaza, cutting off cameras and communication shortly before midnight on Saturday. 'All cargo was non-military, civilian and intended for direct distribution to a population facing deliberate starvation and medical collapse under Israel's illegal blockade,'' the group said in a statement. It was the second ship operated by the coalition that Israeli forces prevented in recent months from delivering aid to Gaza. It was reported on Sunday that Jordan and the UAE had begun airdropping aid into the besieged Palestinian territory. But Mr Lazzarini said 'airdrops will not reverse the deepening starvation'. 'They are expensive, inefficient and can even kill starving civilians. It is a distraction & smokescreen,' he said in an X post. 'A manmade hunger can only be addressed by political will. Lift the siege, open the gates and guarantee safe movements with dignified access to people in need. Israel's war on Gaza has killed nearly 60,000 Palestinians, injured over 144,000, and left most of the densely populated coastal territory in ruins and the majority of its 2.2 million people homeless and starving. Israel launched the war in October 2023 after nearly 1,200 Israelis were killed and 251 taken hostage during a Hamas attack.
Business Wire
35 minutes ago
- Business Wire
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
LYON, France--(BUSINESS WIRE)--Regulatory News: We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg ®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants. With robust cGMP manufacturing, proprietary therapies, and a development platform, MaaT Pharma is a global leader in microbiome-based oncology, pioneering full-ecosystem therapies to improve survival in oncology. Since completing enrollment in the ARES trial for Xervyteg ® (MaaT013) in October 2024, MaaT Pharma has steadily advanced its roadmap, reporting topline results in January 2025, submitting the Marketing Authorization Application with the European Medicines Agency in June 2025, and signing an exclusive agreement for marketing and distribution in Europe with Clinigen in July 2025. The €37.5 million financing from the EIB follows a rigorous due diligence process by the EIB and further confirms MaaT Pharma's innovation, strategic vision and operational maturity. This funding is part of a global financial strategy to support the Company's development that combines various non-dilutive and dilutive sources to best preserve shareholder value. Eric Soyer, Chief Financial Officer, MaaT Pharma, said: 'We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg ® (MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company's financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy.' Summary of the main terms and conditions of the Loan and Warrants The loan would be available in four (4) tranches, respectively of €3.5 million for Tranche A, €6.0 million for Tranche B, €8.0 million for Tranche C, and €20.0 million for Tranche D, each tranche with Warrants attached. Disbursement of Tranches 2 to 4 are subject to operational and financing conditions. All Tranches are redeemable after a grace period of 4 years from the date of drawing, with reimbursement over a period of 2 years (Tranche A, B and C, i.e. a maturity of 6 years) to 4 years (Tranche D, i.e. a maturity of 8 years). Each tranche will bear interests at 7%, it being provided that some interests will be deferred and paid at maturity and for Tranche C and Tranche D part of the interest will be paid quarterly. MaaT Pharma will issue warrants to the benefit of EIB at the time of (and subject to) disbursement of each tranche in a number depending, for each relevant tranche, on the amount of the relevant tranche and the average price per share paid by investors in the context of equity injection made prior to disbursement of the relevant tranche (except for tranche A where the average price per share over the last trading days preceding the date of execution of the financing agreement). Each warrant will give right to subscribe to one share at a price per warrant equal to 99% of the average price over a period of 5 trading days preceding the issuance of each Warrant. The Warrants may be exercised at any time following maturity of Tranche A. The Warrants will have a 20-year term. EIB and MaaT Pharma have also agreed on (i) a put option to the benefit of EIB under which MaaT Pharma undertook to acquire from EIB all or part of the Warrants upon occurrence of certain events and (ii) a call option to the benefit of MaaT Pharma under which EIB undertook to sell all its Warrants, upon occurrence of a public tender offer over the securities issued by MaaT Pharma. The Warrants are not transferable, except to affiliates of EIB or except in case of occurrence of certain events (including maturity date of Tranche D). In case of transfer of Warrants to third party, MaaT Pharma shall benefit from a preemptive right to acquire the Warrants first. MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor. About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
Yahoo
an hour ago
- Yahoo
'The air was so dangerous in my Birmingham postcode I ended up on life support'
A Birmingham resident who lived near the city's landmark motorway, the Spaghetti Junction, has revealed how she ended up on life support. Named only as Jenny, the 75-year-old woman said she 'never realised how dangerous the air was' until she was hospitalised with life-threatening pneumonia. Traffic fumes and poor housing conditions were to blame for her deteriorating health, doctors told her at the time. Living next to the busiest motorway in Europe, she also found herself suffering regular asthma attacks just from stepping outside. Read more: Couple who starved their dog told RSPCA inspectors she was 'given to them by drug dealers' The retiree found her health drastically improved when she moved nearer to green spaces and away from the motorway. Speaking as part of a new Health Equals campaign this week, she said: 'I never realised just how dangerous the air I was breathing every day really was, I used to live near Spaghetti Junction, and would suffer regular asthma attacks just from stepping outside my door. "It wasn't until I ended up in hospital with pneumonia and on life support that doctors told me the traffic fumes and my poor housing conditions were to blame. "Everyone deserves clean air – not just those lucky enough to live near green spaces or away from busy roads. My health improved dramatically after I moved and started walking in parks. But not everyone has that choice." Her experience with air pollution comes as Health Equals, a coalition of 85 organisations, revealed World Health Organisation (WHO) air quality guidelines were breached in 35,000 neighbourhoods across Britain. Its report also outlined all 506 schools in Birmingham were in neighbourhoods failing the guidelines, putting 290,000 children at risk of serious long term health problems, including heart disease and stroke. The new findings are being released as part of Health Equals' Make Health Equal campaign, to highlight alarming health inequalities: where toxic air, alongside other issues including poor income, unstable jobs and unsafe homes, are contributing to an alarming 16-year gap in life expectancy across the UK. Health Equals is calling for a cross-government strategy that prioritises action on these essential building blocks of health, to stop lives being cut short. City environment boss Coun Majid Mahmood said: "Poor air quality is a major risk to public health, and that is why we are committed to improving the city's air through our clean air strategy. 'Data published in October 2023 showed that our work to address the air pollutant, nitrogen dioxide, is delivering results, with pollution levels in Birmingham city centre slashed by almost 40 per centr since 2016, driven in part by the introduction of the Clean Air Zone. 'Across the city, a dedicated air quality monitoring programme of potential 'hotspots' in Birmingham has found that all sites are within the annual mean air quality objective. This three year monitoring project concluded in 2024 and sought to identify any locations where concentrations of nitrogen dioxide might exceed the annual mean air quality objective. I am pleased to confirm our evidence suggests that outside of the city centre area, air quality concentrations are within legal limits. 'We also monitor particulate matter, both coarse and fine fractions (PM10 and PM2.5), and all of our sites continue to show compliance with legal limits set by Government. We will continue to work with Government to further drive down concentrations of fine particles as we know these are the largest risk to health and we have extended our monitoring network to this end. 'This is supported by our mission to install year-round air monitoring equipment in schools a key component in this. These monitors come in tandem with accompanying education resources and lesson plans helping to inspire a new generation of Clean Air champions. Our work in this area is underpinned further by projects like 'Car Free School Streets', which seeks to reduce emissions during rush hour, driven by readings from council monitoring data showing that the school gates are among the most polluted parts of the city. 'The school sensor programme has the co-benefit of providing monitoring data for fine particulate matter, recognised as a key pollutant in a range of adverse health outcomes such as heart disease, lung diseases and cancers. 'Furthermore, surplus revenues from the Clean Air Zone are feeding directly into our transport plan, enabling us to work in partnership with the West Midlands Combined Authority to support schemes related to active travel, improve public transport infrastructure, and manage demand in the city centre. 'Projects funded by Clean Air Zone revenues include a trial of hydrogen buses, upgrades to the University railway station and new stations on the Camp Hill line, as well as a number of projects within the Cross-City Bus scheme, the expansion of the Car Free School Streets programme, and development of the next phase of the Birmingham Cycle Revolution. Community grants for projects delivering against our priorities have also been provided through the Environment and Transport Neighbourhoods Fund (ETNF). 'Our work towards our clean air objectives continues with the recent launch of a consultation into the renewal of the city's Smoke Control Order, offering greater powers of enforcement against those who breach guidelines. This is just the latest step in our journey, which will not stop until we have achieved our objective of clean air for all residents.' Have you been affected by this. We would like to hear from you. You can contact us by emailing us on
